Claims for Patent: 6,017,747

Summary for Patent: 6,017,747

Title:	Nucleic acids encoding a collagenase
Abstract:	An isolated sequence is provided that encodes crab serine collagenase I. The mature recombinant collagenase (SEQ. I.D. No:4) has a molecular weight of 23,500 and may be expressed in a variety of expression systems for production of readily isolated and reliably pure collagenase with excellent specificity. The recombinant collagenase, however, may be expressed in inactive, zymogen form so as to provide long-term, shelf-stable protease that can be readily activated when collagenolytic activity is desired.
Inventor(s):	Craik; Charles S. (San Francisco, CA), Tsu; Christopher A. (Boulder, CO)
Assignee:	The Regents of the University of California (Oakland, CA)
Application Number:	08/984,417
Patent Claims:	1. An isolated nucleic acid sequence selected from the group consisting of: a nucleic acid that encodes a crab collagenase having the amino acid sequence of SEQ ID NO:4, and a nucleic acid that encodes a crab procollagenase having the amino acid sequence of SEQ ID NO:5. 2. The nucleic acid of claim 1, wherein said nucleic acid encodes a collagenase having the amino acid sequence of SEQ ID NO:4. 3. The nucleic acid of claim 2, wherein said nucleic acid is a deoxyribonucleic acid (DNA). 4. The isolated DNA sequence of claim 2 encoding a collagenase that cleaves collagen at its peptide bonds adjacent to carboxyl termini of arginine, leucine and glutamine residues. 5. A recombinant expression vector containing a nucleic acid selected from the group consisting of: a nucleic acid that encodes a crab collagenase having the amino acid sequence of SEQ ID NO:4, and a nucleic acid that encodes a crab procollagenase having the amino acid sequence of SEQ ID NO:5. 6. A transformant obtained by introducing the recombinant expression vector of claim 5 into a host. 7. An isolated nucleic acid encoding a crab collagenase variant, said variant characterized by an amino acid substitution with respect to Sequence I.D. No:4 or SEQ I.D. No:5, where said substitution is within a site selected from the group consisting of the S1 site of said collagenase, the S1' site of said collagenase, and residue 41 of SEQ ID No:4 or residue 70 of SEQ ID No:5. 8. The nucleic acid as in claim 7 wherein the collagenase variant has a specific P1 preference that is improved with respect to the collagenase of Sequence I.D. No:4. 9. The nucleic acid as in claim 8 wherein the variant has the improved property of having a specific P1 preference for aliphatic amino acids. 10. The nucleic acid as in claim 8 wherein the variant has the improved property of having a specific P1 preference for aromatic amino acids. 11. The nucleic acid as in claim 8 wherein the variant has the improved property of having a specific P1 preference for basic amino acids. 12. The nucleic acid as in claim 8 wherein the variant has the improved property of having a specific P1 preference for acidic amino acids. 13. The nucleic acid as in claim 8 wherein the variant has the improved property of having a specific P2 preference for histidine. 14. The nucleic acid as in claim 7, wherein the variant has no more than four substitutions in the S1 or S1' site. 15. The nucleic acid as in claim 7, wherein the variant has a substitution at an amino acid selected from the group consisting of an amino acid at position 41 of SEQ ID No:4 or position 70 of SEQ ID No:5, an amino acid at position 206 of SEQ ID No:4 or position 235 of SEQ ID No:5, and an amino acid at position 172 of SEQ ID No:4 or position 201 of SEQ ID No:5. 16. The nucleic acid as in claim 15, wherein the variant has a substitution of histidine at position 41 of SEQ ID No:4 or position 70 of SEQ ID No:5 to a non-basic amino acid. 17. The nucleic acid as in claim 16, wherein the variant has a substitution of histidine at position 41 of SEQ ID No:4 or position 70 of SEQ ID No:5 to alanine, glycine or serine. 18. The nucleic acid as in claim 15, wherein the variant has a substitution of aspartic acid at position 206 of SEQ ID No:4 or position 235 of SEQ ID No:5 to an amino acid that is not negatively charged. 19. The nucleic acid as in claim 18, wherein the variant has a substitution of aspartic acid at position 206 of SEQ ID No:4 or position 235 of SEQ ID No:5 to glycine. 20. The nucleic acid as in claim 15, wherein the variant has a substitution of glycine at position 172 of SEQ ID No:4 or position 201 of SEQ ID No:5 to a negatively charged amino acid. 21. The nucleic acid as in claim 20, wherein the variant has a substitution of glycine at position 172 of SEQ ID No:4 or position 201 of SEQ ID No:5 to aspartic acid. 22. The nucleic acid as in claim 7, wherein said nucleic acid is a deoxyribonucleic acid (DNA). 23. The nucleic acid as in claim 7, wherein said nucleic acid is contained in an expression vector.

Details for Patent 6,017,747

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Smith & Nephew, Inc.	SANTYL	collagenase	Ointment	101995	06/04/1965		2016-05-09